Leerink Partners Maintains Underperform on Moderna, Raises Price Target to $18

Moderna -1.35% Pre

Moderna

MRNA

52.84

50.62

-1.35%

-4.21% Pre
Leerink Partners analyst Mani Foroohar maintains Moderna (NASDAQ: MRNA) with a Underperform and raises the price target from $15 to $18.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via